Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma

References

• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046–1060. PubMed PMID: 21410373.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• de Mel S, Chen Y, Gopalakrishnan SK, et al. The Singapore Myeloma study group consensus guidelines for the management of patients with multiple myeloma. Singapore Med J. 2017Feb;582:55–71. PubMed PMID: 27609508; PubMed Central PMCID: PMCPMC5311886. eng
   PubMed Web of Science ®Google Scholar
• Hart AJ, Jagasia MH, Kim AS, et al. Minimal residual disease in myeloma: are we there yet? Biol Blood Marrow Transplant. 2012 ;18(12):1790–1799. 2012/12/01/.
   PubMed Web of Science ®Google Scholar
• Laubach J, Garderet L, Mahindra A, et al. Management of relapsed multiple myeloma: recommendations of the international Myeloma working group. Leukemia. 2016May;30 5:1005–1017. PubMed PMID: 26710887; eng
   PubMed Web of Science ®Google Scholar
• Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012Jan;261:149–157. PubMed PMID: 21799510; PubMed Central PMCID: PMCPMC4109061. eng
   PubMed Web of Science ®Google Scholar
• Yang Y, Li Y, Gu H, et al. Emerging agents and regimens for multiple myeloma. J Hematol Oncol. 2020;13(1):150. 2020/11/09.
   PubMed Web of Science ®Google Scholar
• Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guidelines. J clin oncol. 2019;37(14):1228–1263. PubMed PMID: 30932732.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Spencer A, Nooka AK, et al. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. Haematologica. 2020;105(2):468–477. PubMed PMID: 31221782; PubMed Central PMCID: PMCPMC7012498. eng.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, et al.Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–1331. PubMed PMID: 27705267
   PubMed Web of Science ®Google Scholar
• Bahlis NJ, Dimopoulos MA, White DJ, et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. PubMed PMID: 32001798; eng, Leukemia. 2020 Jul;34(7):1875–1884.
   PubMed Web of Science ®Google Scholar
• Carlson JJ, Guzauskas GF, Chapman RH, et al. Cost-effectiveness of drugs to treat relapsed/refractory multiple myeloma in the United States. PubMed PMID: 29290170; eng, J Manag Care Spec Pharm. 2018 Jan;24(1):29–38.
   PubMed Web of Science ®Google Scholar
• Zhang TT, Wang S, Wan N, et al. Cost-effectiveness of daratumumab-based triplet therapies in patients with relapsed or refractory multiple myeloma. PubMed PMID: 30006069; eng, Clin Ther. 2018 Jul;40(7):1122–1139.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Surveillance, epidemiology, and end results program. Cancer Stat Facts: Myeloma 2021 [cited 2021 Aug 2nd]. Available from: https://seer.cancer.gov/statfacts/html/mulmy.html
   Google Scholar
• Drug and vaccine evaluation methods and process guide Version 3.0. Singapore: Agency for Care Effectiveness; 2021.
   Google Scholar
• Kaufman JL, Usmani SZ, San-Miguel J, et al. Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) alone in relapsed or refractory multiple Myeloma (RRMM). Blood. 2019;134(Supplement_1):1866.
   Web of Science ®Google Scholar
• Rohatgi A. WebPlot Digitizer 2020 [cited 2021 Apr 26th]; 4.3:[ Available from: https://automeris.io/WebPlotDigitizer/
   Google Scholar
• Guyot P, Ades AE, Ouwens MJNM, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9. 2012/02/01.
   PubMed Web of Science ®Google Scholar
• Department of Statistics Singapore: Age-Specific Death Rates, Annual [cited 2021 30th April]. Available from: https://www.tablebuilder.singstat.gov.sg/publicfacing/createDataTable.action?refId=13249
   Google Scholar
• Zeng X, Peng L, Peng Y, et al. Economic evaluation of adding daratumumab to a regimen of bortezomib + dexamethasone in relapsed or refractory multiple myeloma: based on the latest updated analysis of CASTOR. Clin Ther. 2020Feb;422:251–62.e5. PubMed PMID: 31973936; eng
   PubMed Web of Science ®Google Scholar
• TA427: Pomalidomide with dexamethasone for treating relapsed and refractory multiple myeloma after at least two regimens including lenalidomide and bortezomib (review of TA338). Committee Papers. National Institute for Health and Care Excellence; 2016
   Google Scholar
• TA573: Daratumumab in combination with bortezomib for treating relapsed or refractory multiple myeloma. Committee Papers. National Institute for Health and Care Excellence; 2018.
   Google Scholar
• TA695: Carfilzomib with dexamethasone and lenalidomide for treating multiple myeloma after at least 1 previous therapy. Committee Papers. National Institute for Health and Care Excellence; 2020
   Google Scholar
• Jakubowiak AJ, Campioni M, Benedict Á, et al. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. PubMed PMID: 27224006; eng, J Med Econ. 2016 Nov;19(11):1061–1074.
   PubMed Web of Science ®Google Scholar
• Brown RE, Stern S, Dhanasiri S, et al. Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales. Eur J Health Econ. 2013;14(3):507–514. 2013/06/01.
   PubMed Web of Science ®Google Scholar
• TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies. National Institute for Health and Care Excellence; 2009
   Google Scholar
• Beusterien KM, Davies J, Leach M, et al. Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study. Health Qual Life Outcomes. 2010;8(1):50. 2010/05/18.
   PubMed Web of Science ®Google Scholar
• TA338: Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib. National Institute for Health and Care Excellence; 2015
   Google Scholar
• Pearce F, Lin L, Teo E, et al. Health Technology Assessment and Its Use in Drug Policies: Singapore. Value Health Reg Issues. 2019;18:176–183. 2019/05/01.
   PubMedGoogle Scholar
• Monetary Authority of Singapore: exchange Rates, Yearly [ cited 2021 5th May]. Available from: https://eservices.mas.gov.sg/Statistics/msb/ExchangeRates.aspx
   Google Scholar
• ACE. Agency for Care Effectiveness: ministry of Health, Singapore. [Cited5 May 2021]. Available from: https://www.ace-hta.gov.sg/
   Google Scholar
• Davis S Assessing technologies that are not cost-effective at a zero price. Decision Support Unit, ScHARR, University of Sheffield; 2014
   Google Scholar
• Mateos MV, Nahi H, Legiec W, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020May7;7(5):e370–e380. PubMed PMID: 32213342; eng.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Harousseau JL. Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. Blood. 2016Dec15;128(24):2757–2764. PubMed PMID: 27742709; PubMed Central PMCID: PMCPMC5159700. eng.
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Hulin C, et al. Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: a Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial). Blood. 2015;126(23):391.
   Web of Science ®Google Scholar
• Moreau P, Rajkumar SV. Multiple myeloma–translation of trial results into reality. Lancet. 2016Jul9;388(10040):111–113. PubMed PMID: 27411865; eng.
   PubMed Web of Science ®Google Scholar
• Félix J, Aragão F, Almeida JM, et al. Time-dependent endpoints as predictors of overall survival in multiple myeloma. BMC Cancer. 2013;13(1):122. 2013/03/16.
   PubMed Web of Science ®Google Scholar